Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912763 | 0.91 | ITGB3 (0.50) | TLR2TLR1ITGB3ITGA2BMDM2 | |
| SCHEMBL2854141 | 0.89 | TLR2 (0.53) | TLR2TLR1ITGB3ITGA2BMDM2 | |
| SCHEMBL2854140 | 0.89 | TLR2 (0.53) | TLR2TLR1ITGB3ITGA2BMDM2 | |
| SCHEMBL4906558 | 0.87 | TLR2 (0.47) | TLR2TLR1ITGB3ITGA2BMDM2 | |
| SCHEMBL6752281 | 0.87 | TLR2 (0.47) | TLR2TLR1ITGB3ITGA2BMDM2 | |
| SCHEMBL2853534 | 0.86 | MDM2 (0.45) | TLR2TLR1ITGB3ITGA2BMDM2 | |
| SCHEMBL2853531 | 0.86 | MDM2 (0.45) | TLR2TLR1ITGB3ITGA2BMDM2 | |
| SCHEMBL956359 | 0.85 | BACE1 (0.47) | TLR2TLR1MDM2BACE1MDM4 | |
| SCHEMBL956361 | 0.85 | BACE1 (0.47) | TLR2TLR1MDM2BACE1MDM4 | |
| SCHEMBL13702142 | 0.84 | TLR2 (0.53) | TLR2TLR1ITGB3ITGA2BMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | FERRING B.V. | 2008-10-16 | — | — | US | disclosed |
| US-7335677-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2008-02-26 | — | — | US | disclosed |
| US-20050043299-A1 | Inhibitors of dipeptidyl peptidase iv | FERRING B. V. | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043299-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP9, DPP3 | TLR2 4070/4885TLR1 4461/4885ITGB3 4014/4885 |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | PREP, PEPD, DPP4 | TLR2 4532/4885TLR1 4699/4885ITGB3 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.